Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1994 1
1995 4
1996 4
1997 1
1998 4
1999 2
2000 1
2001 4
2002 2
2003 8
2004 2
2005 6
2006 8
2007 10
2008 13
2009 9
2010 10
2011 4
2012 6
2013 7
2014 8
2015 5
2016 12
2017 6
2018 16
2019 15
2020 22
2021 9
2022 11
2023 19
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

205 results

Results by year

Filters applied: . Clear all
Page 1
Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ. Donker M, et al. Among authors: belkacemi y. Lancet Oncol. 2014 Nov;15(12):1303-10. doi: 10.1016/S1470-2045(14)70460-7. Epub 2014 Oct 15. Lancet Oncol. 2014. PMID: 25439688 Free PMC article. Clinical Trial.
Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.
Bartels SAL, Donker M, Poncet C, Sauvé N, Straver ME, van de Velde CJH, Mansel RE, Blanken C, Orzalesi L, Klinkenbijl JHG, van der Mijle HCJ, Nieuwenhuijzen GAP, Veltkamp SC, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JWS, Belkacemi Y, Petignat P, Schinagl DAX, Coens C, van Tienhoven G, van Duijnhoven F, Rutgers EJT. Bartels SAL, et al. Among authors: belkacemi y. J Clin Oncol. 2023 Apr 20;41(12):2159-2165. doi: 10.1200/JCO.22.01565. Epub 2022 Nov 16. J Clin Oncol. 2023. PMID: 36383926 Clinical Trial.
Radiotherapy of breast cancer.
Hennequin C, Belkacémi Y, Bourgier C, Cowen D, Cutuli B, Fourquet A, Hannoun-Lévi JM, Pasquier D, Racadot S, Rivera S. Hennequin C, et al. Among authors: belkacemi y. Cancer Radiother. 2022 Feb-Apr;26(1-2):221-230. doi: 10.1016/j.canrad.2021.11.013. Epub 2021 Dec 23. Cancer Radiother. 2022. PMID: 34955414
Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial.
Sargos P, Chabaud S, Latorzeff I, Magné N, Benyoucef A, Supiot S, Pasquier D, Abdiche MS, Gilliot O, Graff-Cailleaud P, Silva M, Bergerot P, Baumann P, Belkacemi Y, Azria D, Brihoum M, Soulié M, Richaud P. Sargos P, et al. Among authors: belkacemi y. Lancet Oncol. 2020 Oct;21(10):1341-1352. doi: 10.1016/S1470-2045(20)30454-X. Lancet Oncol. 2020. PMID: 33002438 Clinical Trial.
Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial.
Carrie C, Magné N, Burban-Provost P, Sargos P, Latorzeff I, Lagrange JL, Supiot S, Belkacemi Y, Peiffert D, Allouache N, Dubray BM, Servagi-Vernat S, Suchaud JP, Crehange G, Guerif S, Brihoum M, Barbier N, Graff-Cailleaud P, Ruffion A, Dussart S, Ferlay C, Chabaud S. Carrie C, et al. Among authors: belkacemi y. Lancet Oncol. 2019 Dec;20(12):1740-1749. doi: 10.1016/S1470-2045(19)30486-3. Epub 2019 Oct 16. Lancet Oncol. 2019. PMID: 31629656 Clinical Trial.
Designing clinical trials based on modern imaging and metastasis-directed treatments in patients with oligometastatic breast cancer: a consensus recommendation from the EORTC Imaging and Breast Cancer Groups.
Pasquier D, Bidaut L, Oprea-Lager DE, deSouza NM, Krug D, Collette L, Kunz W, Belkacemi Y, Bau MG, Caramella C, De Geus-Oei LF, De Caluwé A, Deroose C, Gheysens O, Herrmann K, Kindts I, Kontos M, Kümmel S, Linderholm B, Lopci E, Meattini I, Smeets A, Kaidar-Person O, Poortmans P, Tsoutsou P, Hajjaji N, Russell N, Senkus E, Talbot JN, Umutlu L, Vandecaveye V, Verhoeff JJC, van Oordt WMH, Zacho HD, Cardoso F, Fournier L, Van Duijnhoven F, Lecouvet FE. Pasquier D, et al. Among authors: belkacemi y. Lancet Oncol. 2023 Aug;24(8):e331-e343. doi: 10.1016/S1470-2045(23)00286-3. Lancet Oncol. 2023. PMID: 37541279 Review.
Stroma in normal and cancer wound healing.
Huet E, Jaroz C, Nguyen HQ, Belkacemi Y, de la Taille A, Stavrinides V, Whitaker H. Huet E, et al. Among authors: belkacemi y. FEBS J. 2019 Aug;286(15):2909-2920. doi: 10.1111/febs.14842. Epub 2019 Apr 15. FEBS J. 2019. PMID: 30958920 Free article. Review.
In Regard to Goldberg et al.
Morgan DAL, Parks RM, Belkacemi Y. Morgan DAL, et al. Among authors: belkacemi y. Int J Radiat Oncol Biol Phys. 2023 Mar 15;115(4):1011-1012. doi: 10.1016/j.ijrobp.2022.11.032. Int J Radiat Oncol Biol Phys. 2023. PMID: 36822777 No abstract available.
[Biologic effects of high doses per fraction].
Grellier N, Belkacemi Y. Grellier N, et al. Among authors: belkacemi y. Cancer Radiother. 2020 Apr;24(2):153-158. doi: 10.1016/j.canrad.2019.06.017. Epub 2020 Feb 20. Cancer Radiother. 2020. PMID: 32089502 Review. French.
205 results